Endocrinal assessment of chronic obstructive pulmonary disease patients as compared to control groups
DOI:
https://doi.org/10.18203/2320-6012.ijrms20171279Keywords:
COPD, Endocrinal assessment, Growth hormoneAbstract
Background: Hormones also take part in respiratory control via peripheral chemo receptors or by their local effects on the lungs and the airways. In chronic obstructive pulmonary disease patients, respiratory muscles are required to work efficiently than normal individuals to establish a sufficient respiration. Changes in serum hormone levels of COPD patients adversely affect functioning of respiratory muscles. Objective of the study was to assess endocrinal profile in COPD patient with comparable control groups.
Methods: A Hospital based Case control study conducted at Department of Pulmonary Medicine, Late B.R.K.M Government Medical College, Jagdalpur, Chhattisgarh, India during July 2016 to January 2017. Study included 75 diagnosed cases of COPD in which moderate, severe, very severe COPD was 25 in each of this group (per GOLD ‘s guideline) and compared to age matched 25 healthy control.
Results: In this study serum growth hormone and serum testosterone showed significant difference between COPD cases and control group and fair significant difference in serum FSH between COPD cases and control groups. There was no significant correlation between serum growth hormone, serum testosterone and serum FSH with COPD grading. There was no statistically difference observed in serum LH (p=0.425) level between COPD cases and control groups. Present study showed there was statistically difference in FT3, FT4 and TSH level between COPD cases and control groups. There was significant negative correlation between FT4 levels between COPD grading. But no correlation seen between COPD grading and control with respect to serum FT3 and TSH level.
Conclusions: Endocrinal assessment in present study showed significant decrease in serum growth hormone and serum testosterone in COPD patients, which are anabolic hormones. Early detection and correction of such an anabolic hormonal abnormality may prevent skeletal and diaphragmatic muscle weakness, and improve respiratory drive of COPD patients.References
Creutzberg EC, Casaburi R. Endocrinological disturbances in chronic obstructive pulmonary disease. Eur Respir J. 2003;22(46 suppl):76s-80s.
Scalvini S, Volterrani M, Vitacca M, Clark AL, Solfrini R, Panzali AM, et al. Plasma hormone levels and haemodynamics in patients with chronic obstructive lung disease. Monaldi Arch Chest Dis. 1996;51:380-6.
Leach RM, Forsling ML. The effect of changes in arterial PCO2 on neuroendocrine function in man. Exp Physiol. 2004;89:287-92.
Griffin JE, Ojeda SR. Textbook of Endocrine Physiology, 5ed. New York, Oxford University Press. 2004.
Sacheck JM, Ohtsuka A, McLary SC, Goldberg AL. IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am J Physiol Endocrinol Metab. 2004;287:E591-601.
Haren MT, Banks WA, Perry Iii HM. Predictors of serum testosterone and DHEAS in African-American men. Int J Androl. 2008;31:50-9.
Xu ZS, Bao ZY, Wang ZY, Yang GJ, Zhu DF, Zhang L, Tan RM. The changes of Ghrelin, growth hormone, growth hormone releasing hormone and their clinical significances in patients with chronic obstructive pulmonary disease. Zhonghua Nei Ke Za Zhi. 2012;51(7):536-9.
Prokopis K, Ageliki K. Plasma leptin and insulin like growth factor I levels during acute exacerbations chronic obstructive pulmonary disease. BMC Pulm Med. 2009;9:11.
Debigaré R1, Marquis K, Côté CH, Tremblay RR, Michaud A, LeBlanc P, et al. Catabolic/anabolic balance and muscle wasting in patients with COPD. Chest. 2003;124:83-9.
King DA, Cordova F, Scharf SM. Nutritional aspects of chronic obstructive pulmonary disease. Proceedings of the American Thoracic Society. 2008;5(4):519-23.
Schuetz P, Müller B. The hypothalamic-pituitary-adrenal axis in critical illness. Endocrinology and metabolism clinics of North America. 2006;35(4):823-38.
Semple PD, Beastall GH, Watson WS. Serum testosterone depression associated with hypoxia in respiratory failure. Clin Sci (Lond). 1980;58:105-6.
Akbaş T, Karakurt S, Unlügüzel G, Celikel T, Akalin S. The endocrinologic changes in critically ill chronic obstructive pulmonary disease patients. COPD. 2010;7 (4):240-7.
Van Vliet M1, Spruit MA, Verleden G, Kasran A, Van Herck E, Pitta F, et al. Hypogonadism, quadriceps weakness, and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172:1105-11.
Laghi F, Antonescu-Turcu A, Collins E. Hypogonadism in men with chronic obstructive pulmonary disease: prevalence and quality of life. Am J Respir Crit Care Med. 2005;171:728-33.
Daabis RG, Rehem RN, Hassan MM, Khalil GI. Hypogonadism in patients with chronic obstructive pulmonary disease: relationship with airflow limitation, muscle weakness and systemic inflammation. Alex J Med. 2015.
Shaker A, El-Shora A, El-Gammal M, Labib HA. Endocrinal disturbances and systemic inflammatiom in chronic obstructive pulmonary disease (COPD). Egyptian Journal of Chest Diseases and Tuberculosis. 2012;61(3):81-8.
Karadag F, Ozcan H, Karul AB. Correlates of non-thyroidal illness syndrome in chronic obstructive pulmonary disease. Respir Med. 2007;101:1439-46.
Shoukry A, Said NS, Abd-Elrahman MA, Saber T, Fawzy MA, Shalaby S. Thyroid dysfunction and inflammatory biomarkers in chronic obstructive pulmonary disease: Relation to severity and exacerbation. Egyptian J Chest Diseases and Tuberculosis. 2013;62(4):567-74.
Dimopoulou I, Ilias I, Mastorakos G. Effects of severity of chronic obstructive pulmonary disease on thyroid function. Metabolism. 2001;50:1397-401.
